APA (7th ed.) Citation

Bogatkevich, G. S., Highland, K. B., Akter, T., & Silver, R. M. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Wiley.

Chicago Style (17th ed.) Citation

Bogatkevich, Galina S., Kristin B. Highland, Tanjina Akter, and Richard M. Silver. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Wiley.

MLA (9th ed.) Citation

Bogatkevich, Galina S., et al. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Wiley.